Navigation Links
S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
Date:10/25/2011

SINGAPORE, Oct. 25, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.

"Data from Phase 1 and 2 clinical studies have demonstrated that pacritinib is well tolerated and active in the treatment of myelofibrosis, an orphan disease with a high unmet medical need," said Tamar Howson, interim CEO and board member of S*BIO. "We are moving forward with an aggressive and focused development plan with global Phase 3 trials for pacritinib to further demonstrate its clinical benefits in MF patients and to maximise the value of our JAK2 program. We are currently in the process of identifying a suitable partner for the Phase 3 studies and pacritinib's subsequent commercialization."

The primary objective of the double-blind, placebo-controlled Phase 3 studies is to compare the efficacy of pacritinib versus placebo in achieving clinically significant reduction in spleen size in MF patients with splenomegaly. Secondary outcomes of both studies include patient-reported change in the most bothersome symptom identified at baseline, duration of response, as well as overall survival. The trials will enrol up to 500 MF patients.

In Phase 2 studies, treatment with pacritinib resulted in sustained reduction in MF-associated splenomegaly with no evidence of myelosuppression and no exacerbation of cytopenias. Pacritinib is a small molecule JAK2-selective kinase inhibitor that demonstrated high potency in preclinical models against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequency in myeloproliferative disorders such as MF. More than 50% of patients with MF possess the JAK2 mutation.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs including kinases and histone deacetylases (HDAC). Pacritinib, or SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, pracinostat (SB939), is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. More information about S*BIO can be found at www.sbio.com.S*BIO Pte Ltd:Russo PartnersTamar Howson

Tony Russo +1 212-845-4251Interim CEO & Board Member

Tony.Russo@russopartnersllc.comtamarhowson@me.com

Andreas Marathovouniotis +1 212-845-4235Andreas.Marathis@russopartnersllc.com
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
3. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
7. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
8. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
9. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
10. CareFusion Initiates Class I Recall of EnVe Ventilators
11. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... MEMPHIS, Tenn. and BENTON, Ky. , Aug. 2, 2017 /PRNewswire/ ... new member to its environmental services (ES) team to proactively reduce the risk of hospital-acquired ... is a UV disinfection robot that uses UVC light energy to kill deadly pathogens such ... ... Tru-D ...
(Date:7/31/2017)... 31, 2017 Three Tru-D SmartUVC robots have arrived ... Korea . Tru-D, short for "Total Room Ultraviolet Disinfection," is a ... an environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs ... "Although the BAACH has a very ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... ... , has returned home to Indiana, and is now seeing patients at Boling ... ophthalmologist that specializes in the diagnosis and treatment of eye disease, medical retina, ...
(Date:8/23/2017)... ... August 23, 2017 , ... A ... of Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an ... According to the report, a wider scope of physical therapy options is showing ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western North ... at a popular international aesthetics conference for medical professionals about the positive impact ... health and his growing practice. , Dr. George K. Ibrahim shared ...
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, but ... of auto glass for most makes and models, in Grand Prairie, TX, located in the ... They have been a family owned business for the past 40 years with 32 convenient ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Glimpses Of ... understanding of the world. “Glimpses Of Light” is the creation of published author, J.M. ... life in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is ...
Breaking Medicine News(10 mins):